MEA Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2032

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 19
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 DBMR TRIPOD DATA VALIDATION MODEL 25
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MULTIVARIATE MODELLING 29
2.7 MARKET END USER COVERAGE GRID 30
2.8 PROCESS LIFELINE CURVE 31
2.9 DBMR MARKET POSITION GRID 32
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 POTERS FIVE FORCES 42
5 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 43
6 MARKET OVERVIEW 47
6.1 DRIVERS 49
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 49
6.1.2 RISE IN CHRONIC DISEASES 49
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 50
6.1.4 GROWTH IN BIOLOGICS 51
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 51
6.2 RESTRAINTS 52
6.2.1 RISE IN COST OF FORMULATED DRUG 52
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 52
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 52
6.3 OPPORTUNITIES 53
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 53
6.3.2 RISE IN HEALTHCARE EXPENDITURE 53
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 54
6.4 CHALLENGES 54
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 54
6.4.2 STRINGENT REGULATIONS 55
7 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 56
7.1 IMPACT ON PRICE 56
7.2 IMPACT ON DEMAND 56
7.3 IMPACT ON SUPPLY CHAIN 57
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 57
7.5 CONCLUSION 58
8 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 59
8.1 OVERVIEW 60
8.2 TARGET SELECTION 63
8.3 TARGET VALIDATION 63
8.4 HIT-TO-LEAD IDENTIFICATION 64
8.5 LEAD OPTIMIZATION 65
8.6 CANDIDATE VALIDATION 66
9 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 67
9.1 OVERVIEW 68
9.2 FRAGMENT-BASED VARIATION 71
9.3 STRUCTURE BASED DRUG DESIGN 71
9.4 DIVERSITY ORIENTED SYNTHESIS 72
9.5 CHEMOGENOMICS 73
9.6 NATURAL PRODUCTS 74
9.7 OTHERS 75
10 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 76
10.1 OVERVIEW 77
10.2 SMALL MOLECULES 80
10.3 BIOLOGICS 81
11 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 82
11.1 OVERVIEW 83
11.2 ONCOLOGY 86
11.3 NEUROLOGY 86
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 87
11.5 CARDIOVASCULAR DISEASES 88
11.6 DIGESTIVE SYSTEM DISEASES 89
11.7 OTHERS 90
12 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 91
12.1 OVERVIEW 92
12.2 CONTRACT RESEARCH ORGANIZATION 96
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 96
12.4 ACADEMIC AND RESEARCH INSTITUTES 97
12.5 OTHERS 98
13 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY REGION 99
13.1 MIDDLE EAST AND AFRICA 100
13.1.1 SOUTH AFRICA 106
13.1.2 SAUDI ARABIA 108
13.1.3 U.A.E. 110
13.1.4 EGYPT 112
13.1.5 ISRAEL 114
13.1.6 KUWAIT 116
13.1.7 REST OF MIDDLE EAST AND AFRICA 118
14 MIDDLE EAST & AFRICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 119
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 119

15 SWOT ANALYSIS 120
16 COMPANY PROFILE 121
16.1 EUROFINS SCIENTIFIC 121
16.1.1 COMPANY SNAPSHOT 121
16.1.2 REVENUE ANALYSIS 122
16.1.3 COMPANY SHARE ANALYSIS 122
16.1.4 SERVICE PORTFOLIO 122
16.1.5 RECENT DEVELOPMENT 123
16.2 LABCORP DRUG DEVELOPMENT 124
16.2.1 COMPANY SNAPSHOT 124
16.2.2 REVENUE ANALYSIS 125
16.2.3 COMPANY SHARE ANALYSIS 125
16.2.4 SERVICE PORTFOLIO 126
16.2.5 RECENT DEVELOPMENT 126
16.3 CHARLES RIVER 127
16.3.1 COMPANY SNAPSHOT 127
16.3.2 REVENUE ANALYSIS 127
16.3.3 COMPANY SHARE ANALYSIS 128
16.3.4 SERVICE PORTFOLIO 128
16.3.5 RECENT DEVELOPMENTS 128
16.4 WUXI APPTEC 129
16.4.1 COMPANY SNAPSHOT 129
16.4.2 REVENUE ANALYSIS 129
16.4.3 COMPANY SHARE ANALYSIS 130
16.4.4 SERVICE PORTFOLIO 130
16.4.5 RECENT DEVELOPMENTS 130
16.5 EVOTEC SE 131
16.5.1 COMPANY SNAPSHOT 131
16.5.2 REVENUE ANALYSIS 131
16.5.3 COMPANY SHARE ANALYSIS 132
16.5.4 SERVICE PORTFOLIO 132
16.5.5 RECENT DEVELOPMENTS 132
16.6 PIRAMAL PHARMA SOLUTIONS 133
16.6.1 COMPANY SNAPSHOT 133
16.6.2 SERVICE PORTFOLIO 133
16.6.3 RECENT DEVELOPMENTS 133

16.7 THERMO FISHER SCIENTIFIC INC. 134
16.7.1 COMPANY SNAPSHOT 134
16.7.2 REVENUE ANALYSIS 134
16.7.3 SERVICE PORTFOLIO 135
16.7.4 RECENT DEVELOPMENT 135
16.7.4.1 ACQUISITION 135
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 136
16.8.1 COMPANY SNAPSHOT 136
16.8.2 REVENUE ANALYSIS 136
16.8.3 SERVICE PORTFOLIO 137
16.8.4 RECENT DEVELOPMENT 137
16.9 AURELIA BIOSCIENCES 138
16.9.1 COMPANY SNAPSHOT 138
16.9.2 SERVICE PORTFOLIO 138
16.9.3 RECENT DEVELOPMENTS 138
16.10 BIOBLOCKS INC 139
16.10.1 COMPANY SNAPSHOT 139
16.10.2 SERVICE PORTFOLIO 139
16.10.3 RECENT DEVELOPMENT 139
16.11 CERTARA INC 140
16.11.1 COMPANY SNAPSHOT 140
16.11.2 REVENUE ANALYSIS 140
16.11.3 SERVICE PORTFOLIO 141
16.11.4 RECENT DEVELOPMENTS 141
16.12 DOMAINEX 142
16.12.1 COMPANY SNAPSHOT 142
16.12.2 SERVICE PORTFOLIO 142
16.12.3 RECENT DEVELOPMENT 142
16.13 DRUG DISCOVERY ALLIANCES 143
16.13.1 COMPANY SNAPSHOT 143
16.13.2 SERVICE PORTFOLIO 143
16.13.3 RECENT DEVELOPMENT 143
16.14 GENSCRIPT BIOTECH 144
16.14.1 COMPANY SNAPSHOT 144
16.14.2 REVENUE ANALYSIS 144
16.14.3 SERVICE PORTFOLIO 145
16.14.4 RECENT DEVELOPMENT 145

16.15 JUBILANT BIOSYS 146
16.15.1 COMPANY SNAPSHOT 146
16.15.2 SERVICE PORTFOLIO 146
16.15.3 RECENT DEVELOPMENTS 146
16.16 NANOSYN 148
16.16.1 COMPANY SNAPSHOT 148
16.16.2 PRODUCT PORTFOLIO 148
16.16.3 RECENT DEVELOPMENT 148
16.17 NEREID THERAPEUTICS 149
16.17.1 COMPANY SNAPSHOT 149
16.17.2 SERVICE PORTFOLIO 149
16.17.3 RECENT DEVELOPMENT 149
16.18 PFIZER INC. 150
16.18.1 COMPANY SNAPSHOT 150
16.18.2 REVENUE ANALYSIS 150
16.18.3 SERVICE PORTFOLIO 151
16.18.4 RECENT DEVELOPMENTS 151
16.19 SELVITA 152
16.19.1 COMPANY SNAPSHOT 152
16.19.2 REVENUE ANALYSIS 152
16.19.3 SERVICE PORTFOLIO 153
16.19.4 RECENT DEVELOPMENTS 153
16.19.4.1 ACQUISITION 153
16.20 SPECTRIS PLC 154
16.20.1 COMPANY SNAPSHOT 154
16.20.2 REVENUE ANALYSIS 154
16.20.3 SERVICE PORTFOLIO 155
16.20.4 RECENT DEVELOPMENT 155
16.21 SYGNATURE DISCOVERY 156
16.21.1 COMPANY SNAPSHOT 156
16.21.2 SERVICE PORTFOLIO 156
16.21.3 RECENT DEVELOPMENTS 156
16.22 TAROS CHEMICAL GMBH 157
16.22.1 COMPANY SNAPSHOT 157
16.22.2 SERVICE PORTFOLIO 157
16.22.3 RECENT DEVELOPMENT 157
17 QUESTIONNAIRE 158
18 RELATED REPORTS 161